Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Neostigmine
Drug ID BADD_D01553
Description A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
Indications and Usage Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
Marketing Status approved; vet_approved
ATC Code N07AA01; S01EB06
DrugBank ID DB01400
KEGG ID D08261
MeSH ID D009388
PubChem ID 4456
TTD Drug ID D08USJ
NDC Product Code 71872-7178; 43598-528; 43598-529
UNII 3982TWQ96G
Synonyms Neostigmine | Synstigmin | Proserine | Prozerin | Polstigmine | Neostigmine Bromide | Bromide, Neostigmine | Syntostigmine | Neostigmine Methylsulfate | Methylsulfate, Neostigmine | Prostigmine | Prostigmin
Chemical Information
Molecular Formula C12H19N2O2+
CAS Registry Number 59-99-4
SMILES CN(C)C(=O)OC1=CC=CC(=C1)[N+](C)(C)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insomnia17.15.03.002; 19.02.01.002--
Lacrimation increased06.08.02.004--
Laryngeal pain22.12.03.010--
Loss of consciousness17.02.04.004--Not Available
Miosis17.02.11.002; 06.05.03.003--Not Available
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle spasms15.05.03.004--
Muscular weakness15.05.06.001; 17.05.03.0050.000609%
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nodal rhythm02.03.03.021--Not Available
Nystagmus06.05.02.006; 17.02.02.006--
Osteoarthritis15.01.04.001--Not Available
Paralysis17.01.04.004--Not Available
Pollakiuria20.02.02.007--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Respiratory arrest22.02.01.009--Not Available
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Respiratory paralysis22.02.06.003; 17.01.04.0100.000179%Not Available
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Shock24.06.02.002--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Syncope02.11.04.015; 24.06.02.012; 17.02.04.008--
Tachycardia02.03.02.0070.000394%Not Available
Urethral disorder20.07.01.002--Not Available
Urinary incontinence20.02.02.010; 17.05.01.008--
Urinary tract disorder20.08.01.001--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene